Multiple new findings reinforce that weight-loss maintenance is becoming a key competitive battleground for GLP-1-based therapies. In a trial presented at ECO 2026, switching from injectable obesity drugs to daily oral orforglipron supported sustained weight loss, with results published in Nature Medicine. Additional data presented around ECO 2026 suggest that maintaining maximum tirzepatide dosing may help preserve weight loss and cardiometabolic improvements over the long term. Together, the studies highlight how dosing strategy and route of administration may influence durability—often more than initial weight reduction. For developers and payers, these results feed into design choices for next-generation maintenance trials, pricing and access conversations, and long-term adherence strategies.